Annovis Bio, Inc. (07X.F)
- Previous Close
2.2000 - Open
2.0950 - Bid --
- Ask --
- Day's Range
2.0950 - 2.0950 - 52 Week Range
1.0500 - 14.8400 - Volume
8,550 - Avg. Volume
586 - Market Cap (intraday)
40.824M - Beta (5Y Monthly) 1.45
- PE Ratio (TTM)
-- - EPS (TTM)
-1.9700 - Earnings Date Aug 12, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
www.annovisbio.comRecent News: 07X.F
View MorePerformance Overview: 07X.F
Trailing total returns as of 5/30/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 07X.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 07X.F
View MoreValuation Measures
Market Cap
40.25M
Enterprise Value
20.71M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.93
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-91.05%
Return on Equity (ttm)
-280.78%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-29.06M
Diluted EPS (ttm)
-1.9700
Balance Sheet and Cash Flow
Total Cash (mrq)
22.24M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-13.95M